co-CEO
Founder & CEO
Head Of US Site
Head Of Preclinical Unit US
Medical Director
Head of Sales and Business Development
Head of Pre-clinical Unit
Chief Technology Officer
Behavioural Studies Advisor
Shmuel Landau brings over 30 years of experience in general and financial management, as well as business consulting, to his role as co-CEO. His tenure, marked by driving sales growth, enhancing profitability, and leading successful turnarounds, showcases his commitment to results and strategic leadership.
His expertise encompasses leadership, innovation, team building, and the management of diverse teams both locally and internationally. Shmuel holds a BA in Accounting and Economics from Tel Aviv University, is a certified CPA in Israel, and has obtained certifications in Information Technologies Analysis.
Shmuel’s approach is defined by a pragmatic focus on tangible outcomes and operational efficiency, underpinned by his extensive educational background and professional certifications. His leadership is instrumental in navigating our organization through growth and challenges, positioning us for success in a competitive global landscape.
Dr. Lamensdorf, who founded Pharmaseed in 2003, has been responsible for its scientific expansion, national and international collaborations and staff excellence. He was the founder and CEO of PharmaSense in 2001, a biotechnology company that specialized in the treatment of CNS disorders.
Dr. Lamensdorf holds a PhD in Pharmacology from the Faculty of Medicine of the Technion, Israel Institute of Technology, and a BSc and MSc in Clinical Pharmacy from the Hebrew University of Jerusalem Medical School.
He held post-doctoral training programs at the National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH), Bethesda, Maryland and at the Molecular Genetics Department of Israel’s Weizmann Institute of Science.
In 2014, Mark earned his PhD in Biosciences from George Mason University, specializing in virology and immunology.
He then joined Caerus Discovery as a Project Manager (PM). In this role, Mark was entrusted with overseeing and completing sponsor-directed research projects. Beyond managing ongoing studies, he consistently engaged with sponsors to tailor individualized work plans and budgets, supporting ongoing studies and ensuring the timely submission of final reports upon study completion.
Drawing upon a decade of research experience, Mark has repeatedly ensured that sponsor studies are meticulously designed to produce meaningful results on the initial attempt.
He is the inventor of several patents, has authored impactful publications, and has been instrumental in securing multiple research grants.
Dr. Agus is a board-certified neurologist and a seasoned medication and device (including software as medical device) development expert, with more than 20 years of global experience in multiple therapy areas.
Served as Chief Medical Officer with several biotech companies and as a senior leader in clinical development and medical affairs in mid-size and large pharmaceutical companies.
Dr. Udi Gluschnaider is the Head of Sales and Business Development at Pharmassed, having joined the team in 2024. He holds a PhD in Medical Science and a Bachelor’s degree in Animal Science from the Hebrew University, where he also completed his post-doctoral training in Cancer Metabolism.
Throughout his career, Dr. Gluschnaider has held significant roles, including project manager positions at Aposense, LogicBio, Ayala Pharmaceuticals, and Chemomab. Before his current role at Pharmassed, he served as the Director of Preclinical Development at Chemomab Therapeutic. Dr. Gluschnaider brings extensive experience in cancer biology, genetics, gene therapy, imaging, diagnostics, and both in vitro and in vivo models to his role.
His background equips him with a deep understanding of the scientific and business aspects of the pharmaceutical industry, enabling him to lead sales and business development strategies effectively.
Beyond his expertise, Dr. Gluschnaider finds balance in life as an avid marathon runner. This dedication to fitness complements his sharp mind for study design and problem-solving, skills that have greatly contributed to his professional achievements. His commitment to both intellectual pursuits and physical well-being underscores his well-rounded approach to life.
Dr. Perri Rozenberg-Hasson joined the Preclinical Research & Development unit of Pharmaseed in 2018 as a Study Director and has served as the Director of the In-Vitro unit since September 2019.
Perri holds a Ph.D. degree in Immunology, a Master’s degree in Cellular Biology, and a Bachelor’s degree in Biology from Tel Aviv University. In her past positions, Perri served as a Teaching Assistant in Immunology, Virology, Microbiology, and Mycology, as well as a Flow Cytometry Analyzer Instructor at Tel Aviv University and a Research assistant at InSight Biopharmaceuticals.
She specializes in various in-vitro assays, primary cell cultures, in-vivo cancer models, and metabolic models. Dr. Rozenberg-Hasson has published numerous scientific papers, mainly concerning the role of eosinophils in cancer, and respiratory and metabolic disorders.
Prof. Ronnie Levy joined Pharmaseed in 2010 as Liaison to Pharmaseed’s Scientific Advisory Board and has been serving as Chief Science Officer since 2015.
Prof. Levy holds a PhD and MSc in Chemistry from The Hebrew University, completed a post-doctoral training in pharmacology at the Roche Institute for Molecular Biology and has a full professor nomination at Ben-Gurion University, Beer-Sheva. Ronnie formerly served as the Head of the Radiochemistry Department at the Nuclear Research Center in the Negev (NRCN) and served at the Israel Institute of Biological Research (IIBR) for 30 years, 13 of which as Head of the Pharmacology Department. He also served on the Board of Directors of the Dead Sea Bromine Group as head of the Research Committee. Prof. Levy attended several sabbaticals during which he conducted research at renowned institutes.
Specializing in biopharmaceuticals, preclinical studies, pharmacokinetics, and new drug development, Prof. Levy has published numerous scientific papers and patents, mainly concerning the development of therapeutic agents for treating central nervous system disorders.
Ronnie’s motto is “being old is only in your mind”. In other words, you should always keep a young spirit.
Eddy is the Chief Technology Officer at PharmaSeed. Previously, he was the Chief Executive Officer at KulaOmics, a biotech company that specializes in NGS-based MultiOmics technologies. Before KulaOmics, Eddy served as the Director of Screening and Biological Assays at DeepCure, where he led efforts to develop HTS platforms for discovering novel chemical entities. From 2016 to 2022, he was the Head of HTS and Biology at the Blavatnik Center for Drug Discovery, providing leadership in drug discovery research across various programs from early stages to pre-clinical evaluation. Eddy holds a Ph.D. in Cancer Research and Immunology from Tel-Aviv University.
